The Brad Hendricks Law Firm is reviewing potential claims for people who were prescribed Byetta and were later diagnosed with:
- Pancreatic cancer
- Thyroid cancer
On March 13, 2013, the FDA announced that it has received reports of pancreatic cancer and thyroid cancer that may be associated with the use of the following Type II injectible and orally administered diabetes drugs:
- Byetta (Exenatide)
- Victoza (Liraglutide)
- Januvia (Sitagliptin)
- Onglyza (Saxagliptin)
- Tradjenta (Linaglipton)
Byetta is a subcutaneous injection administered twice daily to help reduce blood sugar levels in Type 2 diabetics. The “Byetta Pen” was approved by the FDA in 2005 and has been used by millions throughout the United States of America. Studies and reports have shown that these medications may increase the risk of pancreas damage and chronic pancreatitis, and they may even lead to pancreatic cancer or thyroid cancer and other serious adverse drug events. It also appears that the manufacturers withheld valuable information about the risks associated with these drugs and in fact withheld information to gain approval of newer variations of the drug, including Bydureon, each with the same potential risks. Allegations raised in various lawsuits around the country maintain that the manufacturers:
- Failed to adequately warn about potential side effects, with no mention of pancreatic cancer from Byetta placed on the label;
- Failed to advise physicians about the importance of monitoring for first signs of changes to the pancreas, which may have helped users identify chronic asymptomatic pancreatitis that ultimately led to cancer following Byetta use;
- Failed to sufficiently test Byetta before introducing the diabetes pen, with only a small clinical trial involving only short-term treatment as the basis for approval of the medication, which is now used long term by many diabetics;
- Failed to issue a Byetta recall after it became apparent that the risks outweigh the benefits provided over other, safer alternative diabetes medications.
Byetta Thyroid Cancer
According to the FDA’s drug safety communication concerning Byetta, Januvia, and other similar drugs:
The U.S. Food and Drug Administration (FDA) is evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of pancreatitis, or inflammation of the pancreas, and precancerous cellular changes called pancreatic duct metaplasia in patients with type 2 diabetes treated with a class of drugs called incretin mimetics.
Byetta is one of these drugs.
Pancreatic Cancer Symptoms
Pancreatic cancer symptoms include weight loss, jaundice, dark urine, light stool, itching, nausea, vomiting, abdominal pain, back pain, and enlarged lymph nodes in the neck.
Additional symptoms include bloating, nausea, diarrhea, loss of appetite, and elevated blood sugar.
Thyroid Cancer Symptoms
Symptoms of thyroid cancer can include a lump or swelling in the neck, pain in the neck or ears, difficulty swallowing or breathing, hoarseness not related to a cold, and a cough that continues and is not related to a cold.
Do I have A Diabetes Drug Cancer Lawsuit?
If you or a loved one has taken Byetta, Victoza, Januvia, Onglyza or Tradjenta, and have been diagnosed with thyroid cancer or pancreatic cancer, or if you have had a loved one who has died and you believe that your loved one’s death may have been caused by one of these drugs or medications, please contact the The Brad Hendricks Law Firm for a free, confidential consultation by telephone at (501) 221-0444 or toll-free at (800) 603-5100. You may also contact us via e-mail through our website. You can count on us to fight for the compensation you deserve.